Click on a filter below to refine your search. Remove a filter to broaden your search.
Vaccine hesitancy varied considerably; 12.1% of vaccinated individuals were hesitant about booster doses.
Molnupiravir and nirmatrelvir-ritonavir combination therapy should be considered for patients within five days of symptom onset.
The risk for death remains significantly elevated in the third year, as is risk for incident postacute sequelae of COVID-19.
A reduced risk of hospitalization or death was seen at 28 days; a lower risk was seen for all individual mAb products.
Individuals with breakthrough infection have an increased risk for death and postacute sequelae compared with contemporary controls.
No significant difference was seen in cycle threshold values based on variant, regardless of vaccination status.
Noninferiority was established with respect to time to sustained clinical recovery for adults at high risk for progression.
Absolute differences seen in vaccine effectiveness for the delta versus the alpha variant were more marked after one dose.
Pfizer vaccine effectiveness against omicron was 70% compared with 93% against hospitalization for COVID-19 during delta’s predominance.
No increase was seen in the incidence of myocardial infarction, stroke or pulmonary embolism among those aged 75 years or older in France.